![moderate intensity statin moderate intensity statin](https://www.zypitamag.com/wcm-docs/images/dosing/statin_therapy_table.png)
![moderate intensity statin moderate intensity statin](https://image2.slideserve.com/5329483/statin-safety-recommendations-1-l.jpg)
In this analysis, incidence rates for the JUPITER primary endpoint were 11. Data are shown for the placebo group (white bars) and for those allocated to rosuvastatin who had no reduction or an increase in low-density lipoprotein cholesterol (pink), a >0 but 0 but <50% (light green) and 838 individuals (10.6%) experienced no reduction or an increase in non-HDLC compared with baseline (pink).
Moderate intensity statin trial#
Waterfall plot for individual trial participants allocated to rosuvastatin 20 mg for the per cent change in low-density lipoprotein cholesterol (left) and concordant incident event rates (per 1000 person-years) for the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin primary endpoint (right). person-years for those in the no LDLC reduction, LDLC reduction <50%, and LDLC reduction ≥50% groups, respectively ( P = 0.001) ( Table 1). Specifically, in this subgroup, incidence rates for the primary trial endpoint were 18.4, 19.8, 5.4, and 4. See page 1380 for the editorial comment on this article (doi:10.1093/eurheartj/ehw102) IntroductionĬurrent statin guidelines in Europe and Canada advocate achieving a fixed low-density lipoprotein cholesterol (LDLC) target or attaining a ≥50% reduction in LDLC, 1, 2 while current US guidelines advocate the use of statin therapies that reduce LDLC by = 2.0 mg/L, and triglycerides 0% but 0 but 50 mg/dL but <75 mg/dL, similar findings were observed. LDLC, Statin therapy, Apolipoprotein B, Guidelines, Prevention, PCSK9 Similar relationships between % reduction and clinical outcomes were observed in analyses focusing on non-HDLC or apolipoprotein B. person-years for those in the placebo, no LDLC reduction, LDLC reduction <50%, and LDLC reduction ≥50% groups, respectively. These % LDLC reductions directly related to the risks of first cardiovascular events at trial completion, incidence rates for the primary endpoint were 11.2, 9.2, 6.7, and 4. Among rosuvastatin allocated participants, 3640 individuals (46.3%) experienced an LDLC reduction ≥50% 3365 individuals (42.8%) experienced an LDLC reduction >0 but <50% and 851 individuals (10.8%) experienced no reduction or an increase in LDLC compared with baseline. In a randomized trial of 17 082 initially healthy men and women with median baseline LDLC of 108 mg/dL (interquartile range 94–119), we (i) used waterfall plots to assess the variability in LDLC response to rosuvastatin 20 mg daily and (ii) evaluated the impact of reaching ≥50% reductions in LDLC on risk of developing the first cardiovascular events.